Abstract:Anna Viola, 1 Maria Giulia Demarzo, 1, 2 Alfredo Abbruzzese, 1, 3 Marco Muscianisi, 1 Michele Francesco Chiappetta, 1, 3 Giuseppe Costantino, 1 Omar Ksissa, 1, 3 Angela Alibrandi, 4 Walter Fries 1 1 Department of Clinical and Experimental Medicine, IBD-Unit, University of Messina, Messina, Italy; 2 Department of Internal Medicine, Ospedale Policlinico San Martino-IRCCS per l'Oncologia, Gastroenterology Unit, University of Genoa, Genoa, Italy; 3 Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, PROMISE, Gastroenterology & Hepatology Unit, University of Palermo, Palermo, Italy; 4 Department of Economics; Unit of Statistical and Mathematical Sciences, University of Messina, Messina, Italy Correspondence: Anna Viola, Clinical Unit of Gastroenterology and Chronic Bowel Disorders, Department of Clinical and Experimental Medicine, Via Consolare Valeria 1, Messina, 9815, Italy, Tel +39 3338377928, Email Purpose: New therapeutic approaches for ulcerative colitis (UC) are now available, but there is still no robust evidence for predictors of poor outcomes. We aimed to evaluate the factors associated with a chronic active UC disease course. Patients and Methods: Data of all UC outpatients followed for at least 3 years after diagnosis between 2005 and 2018 were retrospectively collected. The primary aim was to identify risk factors for chronic active disease 3 years after diagnosis. Moreover, the following variables were investigated: proximal disease extension or disease regression, proctocolectomy, early use of biologics (BIO) or immunomodulators (IMM), hospitalization, colorectal cancer, and adherence. We defined adherence as both, taking the prescribed therapy and constancy in scheduled follow-up visits. Results: A total of 345 UC patients followed for a median period of 82 months were included. Patients with extensive colitis at diagnosis had a higher rate of chronic active disease 3 years after diagnosis (p< 0.012) together with a higher rate of surgery (p< 0.001) at maximum follow-up. Patients with pancolitis showed significant disease regression over time (51%) without differences in treatment. The only factor associated with chronic active disease was non-adherence (p < 0.03; OR 0.49, 95% CI: 0.26– 0.95). Adherent patients developed chronic active disease (p< 0.025) less frequently but did receive more frequent IMM (p< 0.045) or BIO (p< 0.009) therapy. Conclusion: Patients diagnosed with pancolitis were more likely to have chronic active disease and to undergo colectomy. The only predictor for developing chronically active UC regardless of disease extension was the lack of adherence to therapy within the first 3 years after diagnosis, underlining the importance of tight control of UC patients and the need to timely identify potential risk factors for non-adherence. Keywords: outcome, adherence, surgery, hospitalization, disease course Ulcerative Colitis (UC) is a chronic, potentially progressive and disabling disease that may extend to the entire colon. The clinical course of UC including the risk for surgery is still difficult to predict being characterized by periods of remission and exacerbation which have variable duration. A discrete percentage of patients will develop chronic active disease leading to very poor quality of life (QoL) and a high rate of surgery. 1,2 In a recent paediatric study, 3 the clusters adopted by Henriksen et al 4 were investigated during the first 5 years after diagnosis showing that more than 30% of the patients will develop a chronic active or intermittent disease course despite appropriate treatment. A timely identification of patients with a more disabling disease course over time would be helpful in order to recognize who to treat with a more aggressive therapy aimed to prevent complications and irreversible tissue damage, while, in those with indolent disease, overtreatment may be avoided, and consequently, potential side effects. However, despite numerous studies having been conducted, we are not yet able to stratify the majority of patients according to the risk for developing a more aggressive disease over time. 5 Unfortunately, beyond the four items of the risk matrix model proposed by Monstad et al 6 with important negative predictors such as age <40 years at diagnosis, pancolitis, signs of systemic inflammation and the early need for systemic steroids, with a colectomy rate that reaches 40% at 10 years after diagnosis, in the case of the presence of all four predictors, little progress has b -Abstract Truncated-

Su1926 – Risk of Infections and Hospitalisations in Inflammatory Bowel Disease and Other Immune-Mediated Diseases on Thiopurine Therapy: A Population-Based Study

Assessing Oral Medication Adherence and Identifying Predictors of Low Adherence in Chinese Inflammatory Bowel Disease Patients

The impact of medication belief on adherence to infliximab in patients with Crohn's disease

P252 Low adherence is associated with worse disease course in Ulcerative Colitis: a retrospective study from a single referral center

A Survey of Pregnancy Outcomes for Women of Childbearing Age with Inflammatory Bowel Disease in South China

P479 Trends in Medication Use and Treatment Patterns in Chinese Patients with Inflammatory Bowel Diseases: A Multicenter Cohort Study from 1999 to 2020

Medication adherence to inflammatory bowel disease medications in Aotearoa New Zealand and correlation with health outcomes: A nationwide database analysis

Low Adherence is Associated with Chronic Active Disease in Ulcerative Colitis: A Retrospective Study from a Single Referral Center

P298 Adherence to diagnostic and treatment recommendations for the management of acute severe ulcerative colitis: a prospective and multinational study

P1075 Outcomes in patients stopping biologic during the first trimester of pregnancy : a retrospective monocentric study

DOP80 Prevalence and factors associated with Inflammatory Bowel Disease (IBD) activity during pregnancy: updated data from the DUMBO Registry

OA22 Pregnancy in connective tissue diseases: a 30 year follow-up study of 465 pregnancies from a Spanish monocentric registry

P846 Impact of 5-ASA discontinuation in children with ulcerative colitis under biological therapy

Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study

Polypharmacy in Patients With Inflammatory Bowel Disease: Prevalence and Outcomes in a Single-center Series

De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice

Steroid dependency and trends in prescribing for inflammatory bowel disease - a 20-year national population-based study

P1078 The influence of different 5-aminosalicylic acid preparations on mercaptopurine metabolism

N17 Exploration of medication non-adherence in Inflammatory Bowel Disease patients: A systematic review

Early therapeutic drug monitoring helps to identify inflammatory bowel disease patients with a high risk to fail thiopurine treatment

P896 You Can Lead a Horse to Water But You Can’t Make it Drink: A Study on Medication Adherence of Inflammatory Bowel Disease Patients in Ireland